Zydus Lifesciences Board to Consider Equity Share Buyback Proposal on May 19, 2026

Zydus Lifesciences Limited has notified the BSE and the National Stock Exchange of India of an upcoming Board of Directors meeting scheduled for Tuesday, May 19, 2026. At this meeting, the Board will consider a proposal for the buyback of fully paid-up equity shares of the Company, along with all matters necessary and incidental thereto.

Board Meeting and Buyback Proposal

The intimation, issued on May 13, 2026, is in furtherance of an earlier communication dated May 8, 2026, regarding the scheduled Board meeting. The buyback proposal will be considered in accordance with the applicable provisions of the Companies Act, 2013 (including the rules and regulations framed thereunder), the Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018, as amended, and other applicable laws. The filing was made under Regulation 29(1)(b) and Regulation 29(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Parameter:	Details
Board Meeting Date:	Tuesday, May 19, 2026
Intimation Date:	May 13, 2026
Earlier Intimation Date:	May 8, 2026
Proposal Under Consideration:	Buyback of fully paid-up equity shares
Applicable Regulation:	Regulation 29(1)(b) and 29(2) of SEBI LODR Regulations, 2015

Trading Window Closure

In connection with the proposed buyback, the trading window as per the SEBI (Prohibition of Insider Trading) Regulations, 2015 will remain closed for all Directors and Designated Persons of the Company until Thursday, May 21, 2026. The trading window will reopen for trading on and from Friday, May 22, 2026. The trading window is also deemed to be closed with respect to the aforementioned buyback proposal, in accordance with applicable laws.

Trading Window Status:	Date
Window Closed Until:	Thursday, May 21, 2026
Window Reopens From:	Friday, May 22, 2026

Filing Details

The regulatory filing was signed by Dhaval N. Soni, Company Secretary and Compliance Officer (Membership No. FCS7063) of Zydus Lifesciences Limited. The Company is headquartered at Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Ahmedabad, Gujarat.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+2.02%	+7.59%	+9.68%	+7.12%	+11.98%	+63.93%

Zydus Lifesciences Limited has informed the stock exchanges that Mr. Apurva S. Diwanji (DIN: 00032072) has ceased to serve as Director, including in his capacity as Independent Director, effective Tuesday, May 12, 2026. The cessation follows the completion of his tenure and has been disclosed pursuant to Regulation 30 read with Clause 7 of Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with the SEBI Master Circular dated January 30, 2026.

Director Cessation Details

The company filed the requisite disclosure with BSE Limited and the National Stock Exchange of India Limited on May 13, 2026. The key details of the change, as per the SEBI Master Circular, are outlined below:

Parameter:	Details
Name of Director:	Mr. Apurva S. Diwanji (DIN: 00032072)
Reason for Cessation:	Ceased as Director (including as Independent Director) consequent upon completion of tenure
Date of Cessation:	Effective Tuesday, May 12, 2026
Relationship with Directors/KMP:	Not Applicable

Company's Acknowledgement

Zydus Lifesciences placed on record its sincere appreciation for the valuable contributions made by Mr. Diwanji during his tenure. The company also expressed gratitude for his dedication, integrity, and professional expertise, which enriched its deliberations and decision-making processes. The disclosure was signed by Dhaval N. Soni, Company Secretary and Compliance Officer (Membership No. FCS7063), on May 13, 2026.